Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in moderate to severe myasthenia gravis
NCT03052751Phase 2Completed
- Sponsor
- UCB
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of rozanolixizumab in myasthenia gravis (MG) (2 arms), sponsored by UCB. Primary endpoint: Quantitative Myasthenia Gravis Score at Day 29. Started May 2017; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03052751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052751.